DBV Technologies SA Sponsored ADR Aktie News
20,78 $
10,53 %
vorgestern
Nasdaq,
16. Januar, 22:00 Uhr
tracken
DBV Technologies SA Sponsored ADR Aktie News
Neutral
GlobeNewsWire
●
ein Tag alt
Châtillon, France, January 16, 2026 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing The Company is sufficiently funded to support operations and commercial preparedness, including infrastructure buildup, to launch the VIASKIN® Peanut patch in children 4 to 7 years old in the U.S., if ...
Neutral
GlobeNewsWire
●
5 Tage alt
Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
Neutral
GlobeNewsWire
●
12 Tage alt
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
Positiv
Investors Business Daily
●
etwa ein Monat alt
Shares of DBV Technologies launched Wednesday after the company reported promising results for its peanut allergy treatment.
Neutral
Seeking Alpha
●
etwa ein Monat alt
DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript
Neutral
GlobeNewsWire
●
2 Monate alt
Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN ® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Company remains on track for VITESSE topline data in Q4 of this year DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceut...
Neutral
GlobeNewsWire
●
2 Monate alt
Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2 nd Annual Healthcare Innovation Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual ...
Neutral
GlobeNewsWire
●
3 Monate alt
Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Kevin Trapp as Chief Commercial Officer, effective immediately. In his role, Mr.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
